Remsima Powder for Concentrate for Solution for Infusion

Manufacturer
Celltrion, Inc.(KOREA,SOUTH)

Registraction Number
MAL15015118ACRZ


Content:

• Active Ingredient: Infliximab (biosimilar)
• Excipients: Various inactive ingredients to stabilize the powder

• Crohn's Disease: Used to reduce signs and symptoms and induce and maintain remission.
• Ulcerative Colitis: Used to induce and maintain remission.
• Rheumatoid Arthritis: Used to reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function.
• Ankylosing Spondylitis: Used to reduce signs and symptoms.
• Psoriatic Arthritis: Used to reduce signs and symptoms.
• Plaque Psoriasis: Used to reduce the signs and symptoms of severe plaque psoriasis in adults who have not responded to other systemic therapies.

1. Dosage and Administration: The dosage and administration should be determined by a healthcare provider based on the specific medical condition and patient needs. It is typically administered via intravenous infusion.
2. Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
3. Handling: Use aseptic techniques to avoid contamination. Dispose of syringes and needles safely after use.
4. Monitoring: Regular monitoring of the patient's condition and any potential side effects as advised by the healthcare provider.